Loading quotes...

Forecast

The analysts' average price target is €12.64 (+15.86%). The median is €12.97 (+18.88%).

Buy	9
Hold	0
Sell	0

News Go to news feed

Cellebrite plans to relocate corporate headquarters from Israel to the US

Cellebrite’s board has approved a restructuring that would place a new US parent company at the top of the group’s corporate structure. The move is subject to shareholder and regulatory approval and is expected to be completed by H1 2027. CEO Shiv Ramji cites growth in key markets, greater attractiveness to investors and possible index inclusion as reasons; further details will be disclosed via SEC filings. » More on de.investing.com
Cellebrite brings AI tool Genesis to enterprises and expands international availability

Cellebrite is making its AI-powered investigation tool Genesis generally available to enterprises and is expanding the market to countries such as Australia, the United Kingdom and soon the EU. Genesis, which has already been used by law enforcement since June 2026, is now intended for internal investigations such as employee misconduct, financial fraud, M&A due diligence, insider threats and compliance. At the same time, the company is introducing the Deep Investigator feature to extract hard-to-access mobile data and plans to add additional features and data sources in the coming months. » More on de.investing.com
Cellebrite DI: 30% sell-off as entry opportunity, JPMorgan sees over 40% potential

Cellebrite DI was punished by more than 30% at times after the Q2 results and the surprise CEO change, but is being viewed as a buying opportunity. Criticisms include longer sales cycles and slower monetization progress on product updates, while the core story remains intact according to the report. JPMorgan sees more than 40% upside; the price-to-sales (P/S) ratio is below 5 after the pullback and Shiven Ramji takes over the CEO role immediately. » More on finanzen.net

Financials

In the last quarter, CELLEBRITE DI LTD had revenue of €114.9M and net profit of €5.58M

(EUR)	June 2026	YoY
Revenue	114.9M	19.56%
Gross profit	92.82M	14.44%
Net profit	5.58M	66.22%
EBITDA	14.49M	44.03%

Fundamentals

Metric	Value
Market capitalization	€2.76B
Number of shares	251.34M
52-week high/low	€17.87 - €8.57
Dividends	No
Beta	1.13
P/E ratio	52.17
PEG ratio	0.60
P/B ratio	5.65
P/S ratio	6.00

Company profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations. Its DI platform allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations and solutions are used in a various case, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, intellectual property theft, and civil litigation. The company's Universal Forensic Extraction Device solution addresses problems in accessing digital information, including complicated device locks, encryption barriers, deleted and unknown content, and other obstacles that can prevent critical evidence from coming to light. It also offers Seeker solution that provides the ability to analyze video footage; OSINT Analyze, a real-time deep dive solution used to analyze open-source information, such as the surface web, deep web, and the dark web; and Crypto Tracer, which analyzes blockchain transactions together with related data from an extensive list of sources to identify and categorize wallets, and transactions. The company serves federal and state and local agencies, as well as enterprise companies and service providers. It has operations in the United States, Germany, Singapore, Australia, Brazil, United Kingdom, France, Canada, Japan, and India. The company was incorporated in 1999 and is based in Petah Tikva, Israel. Cellebrite Mobile Synchronization Ltd. operates as a subsidiary of Sun Corporation.